This website sells research peptides exclusively for scientific and laboratory research purposes.
Do you confirm you are 18+ and accessing this site for legitimate research purposes?
AOD-9604 and Semaglutide represent two fundamentally different approaches to metabolic research. AOD-9604 is a stabilised C-terminal fragment of human growth hormone (hGH176-191) that research has shown acts directly on adipose tissue via beta-3 adrenergic receptor stimulation to promote lipolysis without affecting IGF-1 levels or glucose metabolism. Semaglutide operates through GLP-1 receptor agonism to affect appetite regulation via hypothalamic pathways, slow gastric emptying and stimulate insulin secretion in a glucose-dependent manner. The mechanisms are entirely complementary — AOD-9604 targets peripheral fat tissue directly while Semaglutide targets central appetite and incretin pathways. Research examining both compounds in metabolic models has explored whether their distinct mechanisms could be studied in combination for additive metabolic effects. AOD-9604 has completed Phase 2 clinical trials with a well-documented safety profile, while Semaglutide has an extensive Phase 3 clinical trial literature through the SUSTAIN and STEP trial programmes.
